Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of ABSK-011 with Meals and Omeprazole in Healthy Participants
NCT07700953Phase 1Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Jul 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of irpagratinib in hepatocellular carcinoma (HCC) (4 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Peak concentration at 72 hours, Area under the plasma concentration-time curve from time 0 to infinity at 72 hours and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
irpagratinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07700953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07700953.